Novavax (NVAX) Seeks FDA Nod for Updated COVID-19 Vaccine
https://www.zacks.com/stock/news/2289405/novavax-nvax-seeks-fda-nod-for-updated-covid-19-vaccine?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2289405
Jun 17, 2024 - Novavax (NVAX) seeks FDA???s approval to update its COVID-19 vaccine for the 2024-2025 fall season against current circulating strains, including KP.2 and KP.3.
0
Is It Too Late to Buy Novavax Stock?
https://www.fool.com/investing/2024/06/14/is-it-too-late-to-buy-novavax-stock/?source=iedfolrf0000001
Jun 14, 2024 - Shares of the vaccine maker are trading up 230% this year.
0
A Life Expansion Revolution Is Coming: 3 Stocks That Could Lead the Charge
https://www.fool.com/investing/2024/06/12/a-life-expansion-revolution-is-coming-3-stocks-tha/?source=iedfolrf0000001
Jun 12, 2024 - The integration of AI and healthcare is well underway.
0
Regeneron (REGN), SNY Win FDA Nod for Kevzara Label Expansion
https://www.zacks.com/stock/news/2286897/regeneron-regn-sny-win-fda-nod-for-kevzara-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2286897
Jun 11, 2024 - The FDA approves label expansion of Regeneron (REGN) and Sanofi's Kevzara for the treatment of polyarticular juvenile idiopathic arthritis.
0
Denali's (DNLI) Candidate Selected for FDA's START Pilot Program
https://www.zacks.com/stock/news/2283576/denali-s-dnli-candidate-selected-for-fda-s-start-pilot-program?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2283576
Jun 04, 2024 - Denali's (DNLI) DNL126, an investigational enzyme replacement therapy, gets selected for the START Pilot Program, intended to accelerate the development of rare disease therapies.
0
TEVA Stock Rises 135% in a Year: What's Driving the Recovery?
https://www.zacks.com/stock/news/2283544/teva-stock-rises-135-in-a-year-what-s-driving-the-recovery?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2283544
Jun 04, 2024 - TEVA expects its newer drugs, Austedo, Uzedy and Ajovy, as well as a stable generics business, to help revive top-line growth in future quarters.
0
GSK Stock Dips on Delaware Court Ruling for Zantac Litigation
https://www.zacks.com/stock/news/2282848/gsk-stock-dips-on-delaware-court-ruling-for-zantac-litigation?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2282848
Jun 03, 2024 - GSK shares decline more than 7% in pre-market trading on Monday in response to an unfavorable ruling by a state court in Delaware in the Zantac litigation.
0
FDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD
https://www.zacks.com/stock/news/2282076/fda-delays-decision-on-sanofi-sny-regeneron-dupixent-in-copd?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2282076
May 31, 2024 - Per the FDA, the data submitted by Sanofi (SNY)/Regeneron (REGN) for Dupixent in COPD indication constitutes a major amendment to its previously-submitted data. A final decision is expected by Sep 27.
0
Pharma Stock Roundup: JNJ, MRK M&A Deals, SNY, RHHBY Drugs' Priority Review & More
https://www.zacks.com/stock/news/2281925/pharma-stock-roundup-jnj-mrk-m-a-deals-sny-rhhby-drugs-priority-review-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2281925
May 31, 2024 - J&J (JNJ) and Merck (MRK) announce the acquisitions of private biotechs. The FDA grants Priority Review tags to Sanofi's (SNY) and Roche's (RHHBY) regulatory applications.
0
Sanofi (SNY) Signs Deal for AI-Powered Drug Development
https://www.zacks.com/stock/news/2276769/sanofi-sny-signs-deal-for-ai-powered-drug-development?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2276769
May 21, 2024 - Sanofi (SNY) inks collaboration deal with Formation Bio and OpenAI to build AI-powered software to advance drug development and create new medicines.
0